Epitinib and AZD3759 are in clinical trials for untreated EGFR-mutant NSCLC with brain metastases and have shown efficacy in patients (Zeng et al., 2015; Zhou et al., 2022). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.